Compass Therapeutics Advances Cancer Research
BOSTON — Compass Therapeutics, Inc. (Nasdaq: CMPX), a promising player in the biotechnology sphere focused on developing innovative therapies for cancer, has made significant strides in its clinical research. The company has announced that the first patient has been dosed in a groundbreaking Investigator Sponsored Trial (IST) evaluating tovecimig, an advanced bispecific antibody treatment, specifically targeting biliary tract cancer (BTC).
First Investigator Sponsored Trial for Tovecimig
This trial marks a pivotal moment for Compass Therapeutics as tovecimig (CTX-009) is introduced in the front-line treatment setting for patients struggling with BTC. Conducted in collaboration with The University of Texas MD Anderson Cancer Center, this trial is highly anticipated due to its potential to change the treatment landscape for this challenging type of cancer.
Significance of the Trial
According to Thomas Schuetz, MD, PhD, the CEO of Compass Therapeutics, the initiation of this study signifies a commitment to enhancing treatment options for patients diagnosed with BTC. He expressed gratitude to the dedicated team at MD Anderson for their pivotal role in the execution of this trial. Schuetz further explains that this IST complements their ongoing Phase 2/3 study of tovecimig, which recently achieved its primary endpoint, indicating promising results ahead.
Trial Design and Objectives
The open-label trial involves integrating tovecimig with a standard first-line treatment protocol that includes gemcitabine, cisplatin, and durvalumab. The trial will enroll approximately 50 patients who exhibit unresectable or metastatic BTC. Initially, a safety run-in phase will assess 12 participants, followed by an expansion phase involving an additional 38 patients to thoroughly investigate the treatment's efficacy.
Goals and Measures of Success
The primary objectives of this trial focus on evaluating the six-month progression-free survival (PFS) and tolerability of the combination therapy. Additionally, they aim to determine the maximum tolerated dose of tovecimig within this regimen. Secondary objectives include measuring overall response rates (ORR), duration of response (DoR), PFS, and overall survival (OS), providing a comprehensive overview of the therapy’s effectiveness.
Introducing Tovecimig: A Dual Action Antibody
Tovecimig, as a bispecific antibody, operates by inhibiting both the Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways. These pathways are essential for tumor growth and angiogenesis, making tovecimig a potentially powerful treatment option in the fight against various solid tumors, including BTC. Preliminary evidence suggests that tovecimig can significantly combat tumor growth, providing hope where traditional treatments have fallen short.
Current Developments in Clinical Trials
Compass Therapeutics is also conducting the COMPANION-002 trial, a Phase 2/3 investigation comparing the efficacy of tovecimig plus paclitaxel against paclitaxel alone. This ongoing trial aims to further validate the therapeutic benefits of tovecimig specifically in advanced metastatic or recurrent biliary tract cancers. The promising data from both trials reinforce Compass's potential as a key player in transforming cancer treatment approaches.
About Compass Therapeutics
Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics is dedicated to pioneering advances in cancer therapeutics. The company’s research is centered on the interplay between angiogenesis and immune response, aiming to create effective therapies for multiple human diseases. Their innovative pipeline is designed to target significant biological pathways crucial for eliciting an effective immune response against tumors, and they’re committed to advancing their promising candidates through clinical stages.
Company Contact Information
For inquiries and further information, individuals can reach out to their investor relations team via email at ir@compasstherapeutics.com. Additionally, media inquiries can be directed to Anna Gifford, Chief of Staff, at media@compasstherapeutics.com or by calling 617-500-8099.
Frequently Asked Questions
What is the purpose of the IST involving tovecimig?
The IST aims to evaluate the safety and efficacy of tovecimig in conjunction with standard treatments for biliary tract cancer.
How many patients will participate in the trial?
Approximately 50 patients diagnosed with unresectable or metastatic biliary tract cancer will be involved in the study.
What are the primary objectives of the trial?
Primary objectives include assessing six-month progression-free survival, tolerability, and determining the maximum tolerated dose of tovecimig.
How does tovecimig work?
Tovecimig functions as a bispecific antibody targeting DLL4 and VEGF-A pathways, which are crucial for tumor growth and angiogenesis.
Who can be contacted for more information about Compass Therapeutics?
For more details, email their investor relations team or reach out to the media contact Anna Gifford.
